Premenstrual syndrome: A mini review

被引:138
作者
Ryu, Aeli [1 ]
Kim, Tae-Hee [2 ]
机构
[1] Soonchunhyang Univ, Coll Med, Dept Obstet & Gynecol, Cheonan, South Korea
[2] Soonchunhyang Univ, Coll Med, Dept Obstet & Gynecol, Bucheon, South Korea
基金
新加坡国家研究基金会;
关键词
Contraceptives; Oral; combined; Premenstrual dysphoric disorder; Premenstrual syndrome; SEROTONIN-REUPTAKE INHIBITORS; DYSPHORIC DISORDER; THERAPY; EFFICACY; WOMEN;
D O I
10.1016/j.maturitas.2015.08.010
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Premenstrual syndrome (PMS) is characterized by recurrent, moderate-to-severe affective, physical, and behavioral symptoms that develop during the luteal menstrual cycle and disappear within a few days of menstruation. Premenstrual dysphoric disorder (PMDD) is a severe and disabling condition that can affect personal relationships and occupational activities. PMS occurs in 30-40% of reproductive-age females; PMDD affects 3-8% of this population. Although the etiology of PMS is unclear, several theories suggest increased sensitivity to normal hormonal changes and neurotransmitter abnormalities. The diagnostic method of PMS is the Daily Record of Severity of Problems, which women with PMS can use to self-report several symptoms and their severity. Although combined oral contraceptives and serotonergic antidepressants are effective drugs, each is a different option for treating PMS/PMDD. Serotonergic antidepressants are the drugs of choice for improving both physical and mood symptoms. Combined oral contraceptives appear to primarily improve physical symptoms. Clinicians should consider each patient's situation individually. Other treatment options include lifestyle modification, cognitive behavioral therapy, and herbal medicine (e.g., chasteberry). (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:436 / 440
页数:5
相关论文
共 27 条
[1]  
ACOG Committee on Practice Bulletins--Gynecology, 2000, Obstet Gynecol, V95, P1
[2]  
Chung Soo-Ho, 2014, J Menopausal Med, V20, P69, DOI 10.6118/jmm.2014.20.2.69
[3]   Update on Research and Treatment of Premenstrual Dysphoric Disorder [J].
Cunningham, Joanne ;
Yonkers, Kimberly Ann ;
O'Brien, Shaughn ;
Eriksson, Elias .
HARVARD REVIEW OF PSYCHIATRY, 2009, 17 (02) :120-137
[4]  
Dennerstein Lorraine, 2009, Menopause Int, V15, P120, DOI 10.1258/mi.2009.009030
[5]   Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review [J].
Dimmock, PW ;
Wyatt, KM ;
Jones, PW ;
O'Brien, PMS .
LANCET, 2000, 356 (9236) :1131-1136
[6]   Daily Record of Severity of Problems (DRSP): reliability and validity [J].
Endicott, J ;
Nee, J ;
Harrison, W .
ARCHIVES OF WOMENS MENTAL HEALTH, 2005, 9 (01) :41-49
[7]  
Girman Andrea, 2003, Am J Obstet Gynecol, V188, pS56, DOI 10.1067/mob.2003.403
[8]   Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies [J].
Halbreich, Uriel ;
Backstrom, Torbjorn ;
Eriksson, Elias ;
O'Bren, Shawn ;
Calil, Helena ;
Ceskova, Eva ;
Dennerstein, Lorraine ;
Douki, Saida ;
Freeman, Ellen ;
Genazzani, Andrea ;
Heuser, Isabella ;
Kadri, Nadia ;
Rapkin, Andrea ;
Steiner, Meir ;
Wittchen, Hans-Ulrich ;
Yonkers, Kimberly .
GYNECOLOGICAL ENDOCRINOLOGY, 2007, 23 (03) :123-130
[9]   Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder? [J].
Halbreich, Uriel ;
O'Brien, Shaughn ;
Eriksson, Elias ;
Backstrom, Torbjorn ;
Yonkers, Kimberly A. ;
Freeman, Ellen W. .
CNS DRUGS, 2006, 20 (07) :523-547
[10]   Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene [J].
Huo, Liang ;
Straub, Richard E. ;
Roca, Catherine ;
Schmidt, Peter J. ;
Shi, Kai ;
Vakkalanka, Radhakrishna ;
Weinberger, Daniel R. ;
Rubinow, David R. .
BIOLOGICAL PSYCHIATRY, 2007, 62 (08) :925-933